Direct comparison of radioimmunoassay and LC–MS/MS for PK assessment of insulin glargine in clinical development

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab. 33, 205–212 (2007).
  Medline CASGoogle Scholar
• 2 Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin. 19, 34–40 (2003).
  Medline CASGoogle Scholar
• 3 Sommerfeld MR, Muller G, Tschank G et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5 (3), e9540 (2010).
  MedlineGoogle Scholar
• 4 Pierre-Eugene C, Pagesy P, Nguyen TT et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One 7(7), e41992 (2012).
  Medline CASGoogle Scholar
• 5 Bowsher RR, Nowatzke WL. Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods. Bioanalysis 3(8), 883–898 (2011).• Highlighted the challenges for determination of insulin and insulin analogues in the regulated bioanalysis.
  CASGoogle Scholar
• 6 Kim S, Yun YM, Hur M, Moon HW, Kim JQ. The effects of anti-insulin antibodies and cross-reactivity with human recombinant insulin analogues in the E170 insulin immunometric assay. Korean J. Lab. Med. 31(1), 22–29 (2011).
  MedlineGoogle Scholar
• 7 Heurtault B, Reix N, Meyer N et al. Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification. Clin. Chem. Lab Med. 52(3), 355–62 (2014)
  Medline CASGoogle Scholar
• 8 Invitron glargine Luminescence Assay Kit, Invitron Ltd, Monmouth, UK. –www.invitron.co.uk/PI-Glargine%20IV2–113L%20r4%20Webfile.pdf, (2013).
  Google Scholar
• 9 Invitron glargine ELISA Assay Kit, Invitron Ltd, Monmouth, UK. www.invitron.co.uk/PI-Glargine-IV2113E-R5-web.pdf, (2013).
  Google Scholar
• 10 Bolli GB, Hahn AD, Schmidt R et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with Type 1 diabetes. Diabetes Care 35(12), 2626–2630 (2012).
  Medline CASGoogle Scholar
• 11 Lucidi P, Porcellati F, Rossetti P et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with Type 2 diabetes. Diabetes Care 35(12), 2647–2649 (2012).
  Medline CASGoogle Scholar
• 12 Mercodia Insulin ELISA and Mercodia Iso-Insulin ELISA, Mercodia AB, Sylveniusgatan 8A, SE-754 50, Uppsala, Sweden. www.mercodia.se/uploads/modules/Mercodia/posters/Iso-Insulin%20ELISA%20and%20Glargine%20handout.pdf
  Google Scholar
• 13 Blackburn, M. Advances in the quantitation of therapeutic insulin analogues by LC MS/MS. Bioanalysis 5(23), 1–14 (2013).• Review article on LC–MS/MS advances in quantification of insulin analogues.
  Google Scholar
• 14 Thevis M, Thomas A, Schanzer W. Doping control analysis of selected peptide hormones using LC–MS (/MS). Forensic Sci. Int. 213(1), 35–41(2011).
  Medline CASGoogle Scholar
• 15 Thomas A, Schanzer W, Delahaut P. Thevis M. lmmunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods 56(2), 230–235 (2012).
  Medline CASGoogle Scholar
• 16 Ho E, Wan T, Wong A, Lam K, Stewart B. Doping control analysis of insulin and its analogues in equine urine by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1218, 1139–1146 (2011).
  Medline CASGoogle Scholar
• 17 Chen Z, Caulfield MP, McPhaul MJ, Reitz RE, Taylor SW, Clarke NJ. Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin. Chem. 59(9), 1349–56 (2013).
  Medline CASGoogle Scholar
• 18 Chambers EE, Legido-Quigley C, Smith N, Fountain KJ. Development of a fast method for direct analysis of intact synthetic insulins in human plasma: the large peptide challenge. Bioanalysis 5(1), 65–81 (2013).
  CASGoogle Scholar
• 19 Chambers EE, Fountain KJ, Smith N et al. Multidimensional LC–MS/MS enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. Anal. Chem. 86(1), 694–702 (2014).
  Medline CASGoogle Scholar
• 20 ADVIA Centaur and ADVIA Centaur XP System, C-peptide (CpS), 129042 Rev. F, 2009–04. http://labmed.ucsf.edu/labmanual/db/resource/proc-Centaur_C-Peptide_Rev_F.pdf
  Google Scholar
• 21 Invitron insulin kit, Invitron Ltd, Monmouth, UK. www.invitron.com
  Google Scholar
• 22 DiaSorin Lianson Insulin Kit, DiaSorin S.p.A, Via Crescentine SNC – 13040 Saluggia (Vercelli), Italy.
  Google Scholar
• 23 Carter P. Preparation of ligand-free human serum for RIA by adsorption on activated charcoal. Clin. Chem. 24(2), 362–264 (1978).
  Medline CASGoogle Scholar
• 24 European Medicine Agency. Guideline on Bioanalytical Method Validation. Committee for Human Medicinal Products, London, UK (2011).
  Google Scholar
• 25 Knutsson M, Schmidt R. LC–MS/MS of large molecules in a regulated bioanalytical environment – which acceptance criteria to apply. Bioanalysis 5(18), 2211–2214 (2013).• Recommended acceptance criteria for LC–MS/MS of large molecules in a regulated bioanalysis.
  CASGoogle Scholar
• 26 Gerich JE. Novel insulins: expanding options in diabetes management. Am. J. Med. 113(4), 308–16 (2002).
  Medline CASGoogle Scholar
• 27 Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet. Med. 30(7), 803–817 (2013).
  Medline CASGoogle Scholar
• 28 Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in Type 1 diabetes subjects. Diabetes Technol. Ther. 13(4), 451–456 (2011).
  MedlineGoogle Scholar
• 29 Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Diabetes Technol. Ther. 14(7), 589–595 (2012).
  Medline CASGoogle Scholar
• 30 Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in Type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30(10), 2447–2452 (2007).
  Medline CASGoogle Scholar
• 31 Soran H, Younis N. Insulin detemir: a new basal insulin analogue. Diabetes Obes. Metab. 8(1), 26–30 (2006).
  Medline CASGoogle Scholar
• 32 Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with Type 2 diabetes mellitus. Int. J. Genet. Med. 4, 827–835 (2011).
  Medline CASGoogle Scholar
• 33 Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr. Rev. 28(6), 625–652 (2007).
  Medline CASGoogle Scholar
• 34 Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with Type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48(3), 460–468 (1999).
  Medline CASGoogle Scholar
• 35 Wasada T, Eguchi Y, Takayama S, Yao K, Hirata Y, Ishii S. Insulin autoimmune syndrome associated with benign monoclonal gammopathy. Evidence for monoclonal insulin autoantibodies. Diabetes Care 12(2), 147–150 (1989).
  Medline CASGoogle Scholar
• 36 Chen JW, Frystyk J, Lauritzen T, Christiansen JS. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with Type 1 diabetes. Eur. J. Endocrinol. 153(6), 907–913 (2005).
  Medline CASGoogle Scholar
• 37 Jaeger C, Winter S, Eckhard M, Hardt P, Brendel MD, Bretzel RG. Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules. Acta Diabetol. 45(3), 191–194 (2008).
  Medline CASGoogle Scholar
• 38 Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 31(2), 53–59 (2010).
  Medline CASGoogle Scholar
• 39 Radermecker RP, Renard E, Scheen AJ. Circulating insulin antibodies: Influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab. Res. Rev. 25(6), 491–501 (2009).
  Medline CASGoogle Scholar